Roivant Sciences ROIV
Roivant Sciences is a biopharmaceutical company that creates and develops subsidiaries ('Vants') to advance innovative therapies, focusing on high unmet medical needs, such as rare and immunological diseases. Roivant Sciences shows exceptional momentum (128.8% in 12 months) but weak fundamentals: very negative operating margin (-25408%), ROIC of -44.13%, and revenue decline of 33.5%, reflecting a development-stage company with high risk and demanding valuation.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Roivant Sciences is a biopharmaceutical company that creates and develops subsidiaries ('Vants') to advance innovative therapies, focusing on high unmet medical needs, such as rare and immunological diseases. Roivant Sciences shows exceptional momentum (128.8% in 12 months) but weak fundamentals: very negative operating margin (-25408%), ROIC of -44.13%, and revenue decline of 33.5%, reflecting a development-stage company with high risk and demanding valuation.
Score by category
| Category | Score |
|---|---|
| Financial health | 4.3 |
| Quality / Moat | 0.5 |
| Valuation | 0.3 |
| Growth | 0.0 |
| Dividend | 1.5 |
| Momentum | 9.8 |
| Risk & Context | 5.4 |
OVERALL SCORE: 2.4/10
Context and risks
Roivant operates in biotechnology, a sector highly sensitive to interest rates due to the long duration of cash flows; the rise in 10-year yields (5.17%) increases the cost of capital and reduces the present value of its pipeline, although its net debt/EBITDA of 2.75 is moderate.
News considered in the analysis
- Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months — El lanzamiento de LISRAYA y los hitos de pipeline son eventos clave que podrían impulsar ingresos futuros, aunque aún no están materializados.
- Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging? — Éxito en Fase 2 para un fármaco pulmonar añade valor potencial al pipeline, pero aún requiere fases posteriores y aprobación.
- Update: US Equity Futures Slightly Lower Pre-Bell as Traders Await Developments in US-Iran Talks — Noticia macro genérica sin impacto directo en Roivant.
- Roivant’s Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss — Fracaso en ensayo clínico de un activo relevante, lo que reduce el valor del pipeline y puede afectar la confianza.
- Roivant (ROIV): $9 Billion Sales Potential Faces a Commercialization Test — El potencial de ventas es alto pero enfrenta riesgos de comercialización, lo que modera el impacto positivo.
Verdict: Hold or avoid: pipeline potential is high, but lack of profitability and recent failure in a key trial justify caution until commercial results are seen.
Main risk: The main risk is dependence on the success of its development pipeline: a failure in a key trial (like IMVT-1402) can sink the value, given it still generates no profits and its operating margin is deeply negative.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →